Physician Second Opinion Network Archives

Viola Zhu is an Associate Clinical Professor of Medicine at the University of California Irvine and an attending physician at the Chao Family Comprehensive Cancer Center.

She earned her medical degree from Fudan University Shanghai Medical College (former Shanghai Medical University) and was in a graduate program in Medical Oncology at the Fudan University Shanghai Cancer Center prior to receiving her PhD degree in Molecular Pathology and Immunology from the University of Medicine and Dentistry of New Jersey.

She completed her residency in Internal Medicine at Englewood Hospital and Medical Center and fellowship in Hematology and Oncology at Boston Medical Center. She is board certified in Internal Medicine, Hematology, and Medical Oncology.

Her clinical focus is lung cancer, and she is actively involved in many early phase trials of novel targeted therapies including those for MET altered lung cancer. She is on the editorial board for Journal of Clinical Oncology and has publications at many journals with high impact factor including New England Journal of Medicine, Journal of Clinical Oncology, and Cancer Discovery.

Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently an Assistant Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal’s primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies (including MET inhibitors) and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology. He is a member of the International Association of the Study of Lung Cancer (IALSC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings.

Bio coming soon…

Karen L. Reckamp, MD, MS is Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai Medical Center. She received a master’s degree in Clinical Investigation from the department of Biomathematics at UCLA. Dr. Reckamp also serves as the Associate Director of Clinical Research for the Samuel Oschin Comprehensive Cancer Institute (SOCCI). She obtained my medical degree at the University of Chicago, Pritzker School of Medicine in 1998 with AOA distinction, and trained in Internal Medicine at Washington University’s Barnes-Jewish Hospital. Dr. Reckamp completed fellowship training in Hematology/Oncology at the David Geffen School of Medicine, UCLA in June 2004, and completed a Master of Science degree in Clinical Research (MSCR).

She leads many phase I, II and III studies funded by the NCI, internal funds and industry. Dr. Reckamp is a member of ASCO, AACR, International Association for the Study of Lung Cancer, and SWOG. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. Dr. Reckamp has been the past recipient of many honors including American Lung Association, Lung Force Honoree in 2018. She has also authored or co-authored many manuscripts in the field of Thoracic Oncology, and has been active in investigation of MET alterations in lung cancer.

Dr. Mansfield is a medical oncologist at Mayo Clinic with a focus on thoracic malignancies and early therapeutics. He is co-director of the Precision Cancer Therapeutics group within the Center for Individualized Medicine. He has played a significant role in clinical trials leading to FDA approval of agents in lung cancer including atezolizumab for small cell lung cancer, pralsetinib for RET-fusion non-small cell lung cancer and the combination of ipilimumab with nivolumab for mesothelioma. His laboratory runs many translational projects to discover and validate biomarkers in thoracic malignancies.

Xiuning Le, MD, PhD is an Assistant Professor in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center.

Dr. Le received her MD from Peking Union Medical College in China and then obtained a PhD in Genetics at Harvard Medical School. Subsequently, she completed her Internal Medicine Residency at the University of Massachusetts Medical Center and the Hematology/Oncology Fellowship at Beth Israel Deaconess Medical Center (BIDMC). After her trainings, she joined MD Anderson as a faculty member in the Department of Thoracic Medical Oncology.

Dr. Le’s clinical focus is on oncogene-driven lung cancers. She applies genomics expertise in her translational work to understand resistance mechanisms to targeted and immunotherapy. Currently, she serves as a PI for multiple trials focusing on EGFR-mutant or MET exon 14 skipping non-small cell lungs. Dr. Le is a recipient of many prestige junior investigator awards, such as stand-up-to-cancer (SU2C)-V scholar, as well as ASCO young investigator award and career development award.

Bio coming soon…

1 2 ›